Stock A244460 OLIPASS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

All News OLIPASS Corporation

Equities

A244460

KR7244460002

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 31/05/2024 am IST 		5-day change 1st Jan Change
482 KRW -3.79% Intraday chart for OLIPASS Corporation +3.88% -37.73%
18/03 OLIPASS Corporation announced that it has received KRW 3.5 billion in funding CI
06/03 OLIPASS Corporation announced that it expects to receive KRW 5 billion in funding CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
OLIPASS Corporation announced that it has received KRW 3.5 billion in funding
CI
OLIPASS Corporation announced that it expects to receive KRW 5 billion in funding
CI
OLIPASS Corporation announced that it expects to receive KRW 12.50000032 billion in funding
CI
OliPass Corporation Discloses Painful But Hilarious Clinical Findings from a Phase 2a Trial in OA Patients with Nav1.7 Selective Inhibitor OLP-1002
CI
OLIPASS Corporation announced that it has received KRW 4.99998978 billion in funding
CI
OLIPASS Corporation announced that it expects to receive KRW 4.999998885 billion in funding
CI
OLIPASS Corporation announced that it expects to receive KRW 4.99998978 billion in funding
CI
OLIPASS Corporation(KOSDAQ:A244460) dropped from S&P Global BMI Index
CI
OLIPASS Corporation Reports Earnings Results for the Full Year Ended December 31, 2022
CI
OliPass Corporation Announces Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration According to Interim Findings from Phase 2A Study in OA Patients
CI
OLIPASS Corporation announced that it expects to receive KRW 2.999989475 billion in funding from BNB Asset Co., Ltd.
CI
Vanda Pharmaceuticals Inc. and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics
CI
OliPass Corporation Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002
CI
OliPass Corporation Announces Commencement of Dosing in Phase 2a Trial for Pain Killer OLP-1002
CI
OLIPASS Corporation Announces SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage
CI
OLIPASS Corporation announced that it has received KRW 35.4996288 billion in funding from a group of investors
CI
OLIPASS Corporation announced that it expects to receive KRW 35.4996288 billion in funding from a group of investors
CI
OLIPASS Corporation(KOSDAQ:A244460) added to S&P Global BMI Index
CI
OLIPASS Corporation announced that it has received KRW 14 billion in funding from KB Securities Co.,Ltd, Daishin Securities Co., Ltd., Mirae Asset Daewoo Co., Ltd., NH Investment & Securities Co., Ltd.
CI
OLIPASS Corporation announced that it expects to receive KRW 14 billion in funding from KB Securities Co.,Ltd, Daishin Securities Co., Ltd., Mirae Asset Daewoo Co., Ltd., NH Investment & Securities Co., Ltd.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A244460 Stock
  4. News OLIPASS Corporation